Automated production technologies for mRNA vaccines and therapeutics
There is huge potential for new mRNA-based pharmaceutical active compounds – following the Comirnaty and Spikevax vaccines, a large number of drug candidates for a wide range of applications have moved into the focus of attention. But the Corona pandemic has also shown that GMP-compliant mRNA manufacturing on an industrial scale is still in an early phase and a limiting factor. The Fraunhofer lighthouse project RNAuto unites the expertise of seven institutes in medicine, biology and engineering around the common goal of automating the manufacturing processes for mRNA drugs. The Fraunhofer approach covers the entire process chain from target sequence design to biological functionality testing of the manufactured nanopackaged mRNA.